P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma — Paula Rodríguez‐Otero (2023) | RDL Network
P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma
Paula Rodríguez‐Otero, Nisha S. Joseph, Shaji Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A Dimopoulos, María‐Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn Sarkaria
Alexander M. Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐François Castilloux, Peter A. Forsberg, Gurdeep Parmar, Axel Tosikyan, Luděk Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau
D. S. Siegel, D. Weber, Constantine S. Mitsiades, Meletios A Dimopoulos, J. L. Harousseau, Syed Rizvi, J. Howe, David Reiser, Kenneth C. Anderson, Paul G. Richardson
Al‐Ola Abdallah, Alexander M. Lesokhin, Tomasz Wróbel, Krzysztof Jamroziak, Dominik Dytfeld, Cyrille Touzeau, Attaya Suvannasankha, Xavier Leleu, Rebecca Silbermann, Abdullah Khan, Shaji Kumar, Morie A. Gertz, Jacob P. Laubach, Ying‐Ming Jou, Merav Bar, Prianka Das, Yu Wang, Korey Demers, Nicholas Stong, Deepak Perumal, Ross La Motte-Mohs, Kylee Maclachlan,
Discussion(0)
No comments yet. Be the first to comment.